Skip to main content
PMC home page
Proceedings of the National Academy of Sciences of the United States of America logoLink to Proceedings of the National Academy of Sciences of the United States of America
. 1989 Jan;86(1):287–291. doi: 10.1073/pnas.86.1.287

Chimeric cytotoxin IL2-PE40 delays and mitigates adjuvant-induced arthritis in rats.

J P Case 1, H Lorberboum-Galski 1, R Lafyatis 1, D FitzGerald 1, R L Wilder 1, I Pastan 1
PMCID: PMC286449  PMID: 2492102

Abstract

Adjuvant arthritis in rats is a T-cell dependent "autoimmune" disease with close similarities to several forms of human arthritis. Injection of mycobacterial adjuvant leads to T-cell activation and proliferation, processes in which the de novo expression of the interleukin 2 (IL-2) receptor plays a pivotal role. The subsequent massive mononuclear cell infiltration of the joints ultimately results in complete joint destruction. Because activation of the helper/inducer subset of T lymphocytes is critical to the establishment of disease, we reasoned that IL2-PE40, a cytotoxic IL-2-Pseudomonas exotoxin fusion protein that targets the membrane-penetration and ADP-ribosylation domains of the toxin to cells bearing the IL-2 receptor, would be an effective and specific therapy. Adjuvant-injected rats were randomized to treatment with IL2-PE40, phosphate-buffered saline, or either of two control proteins related to IL2-PE40 but lacking either the receptor-binding moiety or an enzymatically active toxin domain and previously demonstrated to lack cytotoxicity in vitro. Intraperitoneal IL2-PE40 given before the establishment of overt clinical disease proved an effective and specific modifier of adjuvant arthritis by clinical, histological, and radiographic criteria. Our data suggest that IL2-PE40 may be effective in those diseases in which activated T-cells play an important role.

Full text

PDF
289

Images in this article

289Image
on p.289
289Image
on p.289
289Image
on p.289

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aronson F. R., Libby P., Brandon E. P., Janicka M. W., Mier J. W. IL-2 rapidly induces natural killer cell adhesion to human endothelial cells. A potential mechanism for endothelial injury. J Immunol. 1988 Jul 1;141(1):158–163. [PubMed] [Google Scholar]
  2. Banerjee S., Wei B. Y., Hillman K., Luthra H. S., David C. S. Immunosuppression of collagen-induced arthritis in mice with an anti-IL-2 receptor antibody. J Immunol. 1988 Aug 15;141(4):1150–1154. [PubMed] [Google Scholar]
  3. Bottazzo G. F., Dean B. M., McNally J. M., MacKay E. H., Swift P. G., Gamble D. R. In situ characterization of autoimmune phenomena and expression of HLA molecules in the pancreas in diabetic insulitis. N Engl J Med. 1985 Aug 8;313(6):353–360. doi: 10.1056/NEJM198508083130604. [DOI] [PubMed] [Google Scholar]
  4. Colamonici O. R., Quinones R., Rosolen A., Trepel J. B., Sausville E., Phares J. C., Gress R., Poplack D., Weber J., Schechter G. P. The beta subunit of the interleukin-2 receptor mediates interleukin-2 induction of anti-CD3 redirected cytotoxic capability in large granular lymphocytes. Blood. 1988 Mar;71(3):825–828. [PubMed] [Google Scholar]
  5. Currey H. L., Ziff M. Suppression of adjuvant disease in the rat by heterologous antilymphocyte globulin. J Exp Med. 1968 Jan 1;127(1):185–203. doi: 10.1084/jem.127.1.185. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Decker J. L., Malone D. G., Haraoui B., Wahl S. M., Schrieber L., Klippel J. H., Steinberg A. D., Wilder R. L. NIH conference. Rheumatoid arthritis: evolving concepts of pathogenesis and treatment. Ann Intern Med. 1984 Dec;101(6):810–824. doi: 10.7326/0003-4819-101-6-810. [DOI] [PubMed] [Google Scholar]
  7. Di Stefano R., Mouzaki A., Araneda D., Diamantstein T., Tilney N. L., Kupiec-Weglinski J. W. Anti-interleukin 2 receptor monoclonal antibodies spare phenotypically distinct T suppressor cells in vivo and exert synergistic biological effects. J Exp Med. 1988 Jun 1;167(6):1981–1986. doi: 10.1084/jem.167.6.1981. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Dukovich M., Wano Y., Le thi Bich Thuy, Katz P., Cullen B. R., Kehrl J. H., Greene W. C. A second human interleukin-2 binding protein that may be a component of high-affinity interleukin-2 receptors. Nature. 1987 Jun 11;327(6122):518–522. doi: 10.1038/327518a0. [DOI] [PubMed] [Google Scholar]
  9. Hahn H. J., Kuttler B., Dunger A., Klöting I., Lucke S., Volk H. D., von Baehr R., Diamantstein T. Prolongation of rat pancreatic islet allograft survival by treatment of recipient rats with monoclonal anti-interleukin-2 receptor antibody and cyclosporin. Diabetologia. 1987 Jan;30(1):44–46. doi: 10.1007/BF01788907. [DOI] [PubMed] [Google Scholar]
  10. Herrmann F., Cannistra S. A., Levine H., Griffin J. D. Expression of interleukin 2 receptors and binding of interleukin 2 by gamma interferon-induced human leukemic and normal monocytic cells. J Exp Med. 1985 Sep 1;162(3):1111–1116. doi: 10.1084/jem.162.3.1111. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Holoshitz J., Naparstek Y., Ben-Nun A., Cohen I. R. Lines of T lymphocytes induce or vaccinate against autoimmune arthritis. Science. 1983 Jan 7;219(4580):56–58. doi: 10.1126/science.6336851. [DOI] [PubMed] [Google Scholar]
  12. Holter W., Grunow R., Stockinger H., Knapp W. Recombinant interferon-gamma induces interleukin 2 receptors on human peripheral blood monocytes. J Immunol. 1986 Mar 15;136(6):2171–2175. [PubMed] [Google Scholar]
  13. Hwang J., Fitzgerald D. J., Adhya S., Pastan I. Functional domains of Pseudomonas exotoxin identified by deletion analysis of the gene expressed in E. coli. Cell. 1987 Jan 16;48(1):129–136. doi: 10.1016/0092-8674(87)90363-1. [DOI] [PubMed] [Google Scholar]
  14. JONES R. S., WARD J. R. Studies on adjuvant-induced polyarthritis in rats. II. Histogenesis of joint and visceral lesions. Arthritis Rheum. 1963 Feb;6:23–35. doi: 10.1002/art.1780060104. [DOI] [PubMed] [Google Scholar]
  15. Kelley V. E., Bacha P., Pankewycz O., Nichols J. C., Murphy J. R., Strom T. B. Interleukin 2-diphtheria toxin fusion protein can abolish cell-mediated immunity in vivo. Proc Natl Acad Sci U S A. 1988 Jun;85(11):3980–3984. doi: 10.1073/pnas.85.11.3980. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Kelley V. E., Gaulton G. N., Hattori M., Ikegami H., Eisenbarth G., Strom T. B. Anti-interleukin 2 receptor antibody suppresses murine diabetic insulitis and lupus nephritis. J Immunol. 1988 Jan 1;140(1):59–61. [PubMed] [Google Scholar]
  17. Kirkman R. L., Barrett L. V., Gaulton G. N., Kelley V. E., Ythier A., Strom T. B. Administration of an anti-interleukin 2 receptor monoclonal antibody prolongs cardiac allograft survival in mice. J Exp Med. 1985 Jul 1;162(1):358–362. doi: 10.1084/jem.162.1.358. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Kohashi O., Aihara K., Ozawa A., Kotani S., Azuma I. New model of a synthetic adjuvant, N-acetylmuramyl-L-alanyl-D-isoglutamine- induced arthritis: clinical and histologic studies in athymic nude and euthymic rats. Lab Invest. 1982 Jul;47(1):27–36. [PubMed] [Google Scholar]
  19. Kupiec-Weglinski J. W., Diamantstein T., Tilney N. L., Strom T. B. Therapy with monoclonal antibody to interleukin 2 receptor spares suppressor T cells and prevents or reverses acute allograft rejection in rats. Proc Natl Acad Sci U S A. 1986 Apr;83(8):2624–2627. doi: 10.1073/pnas.83.8.2624. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Larsson P., Holmdahl R., Dencker L., Klareskog L. In vivo treatment with W3/13 (anti-pan T) but not with OX8 (anti-suppressor/cytotoxic T) monoclonal antibodies impedes the development of adjuvant arthritis in rats. Immunology. 1985 Nov;56(3):383–391. [PMC free article] [PubMed] [Google Scholar]
  21. Lorberboum-Galski H., FitzGerald D., Chaudhary V., Adhya S., Pastan I. Cytotoxic activity of an interleukin 2-Pseudomonas exotoxin chimeric protein produced in Escherichia coli. Proc Natl Acad Sci U S A. 1988 Mar;85(6):1922–1926. doi: 10.1073/pnas.85.6.1922. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Mouzaki A., Volk H. D., Osawa H., Diamantstein T. Blocking of interleukin 2 (IL 2) binding to the IL 2 receptor is not required for the in vivo action of anti-IL 2 receptor monoclonal antibody (mAb). I. The production, characterization and in vivo properties of a new mouse anti-rat IL 2 receptor mAb that reacts with an epitope different to the one that binds to IL 2 and the mAb ART-18. Eur J Immunol. 1987 Mar;17(3):335–341. doi: 10.1002/eji.1830170306. [DOI] [PubMed] [Google Scholar]
  23. Obata T., Cheng S. Y. Strip-comb dot immunobinding: a rapid, easy and sensitive method to screen monoclonal antibodies. Biotechniques. 1988 Apr;6(4):299–303. [PubMed] [Google Scholar]
  24. Oldstone M. B. Molecular mimicry and autoimmune disease. Cell. 1987 Sep 11;50(6):819–820. doi: 10.1016/0092-8674(87)90507-1. [DOI] [PubMed] [Google Scholar]
  25. Palacios R., Kiefer M., Brockhaus M., Karjalainen K., Dembić Z., Kisielow P., von Boehmer H. Molecular, cellular, and functional properties of bone marrow T lymphocyte progenitor clones. J Exp Med. 1987 Jul 1;166(1):12–32. doi: 10.1084/jem.166.1.12. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Ranges G. E., Sriram S., Cooper S. M. Prevention of type II collagen-induced arthritis by in vivo treatment with anti-L3T4. J Exp Med. 1985 Sep 1;162(3):1105–1110. doi: 10.1084/jem.162.3.1105. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Rosenstein M., Ettinghausen S. E., Rosenberg S. A. Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin 2. J Immunol. 1986 Sep 1;137(5):1735–1742. [PubMed] [Google Scholar]
  28. Schwimmbeck P. L., Yu D. T., Oldstone M. B. Autoantibodies to HLA B27 in the sera of HLA B27 patients with ankylosing spondylitis and Reiter's syndrome. Molecular mimicry with Klebsiella pneumoniae as potential mechanism of autoimmune disease. J Exp Med. 1987 Jul 1;166(1):173–181. doi: 10.1084/jem.166.1.173. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Shapiro M. E., Kirkman R. L., Reed M. H., Puskas J. D., Mazoujian G., Letvin N. L., Carpenter C. B., Milford E. L., Waldmann T. A., Strom T. B. Monoclonal anti-IL-2 receptor antibody in primate renal transplantation. Transplant Proc. 1987 Feb;19(1 Pt 1):594–598. [PubMed] [Google Scholar]
  30. Taurog J. D., Sandberg G. P., Mahowald M. L. The cellular basis of adjuvant arthritis. I. Enhancement of cell-mediated passive transfer by concanavalin A and by immunosuppressive pretreatment of the recipient. Cell Immunol. 1983 Feb 1;75(2):271–282. doi: 10.1016/0008-8749(83)90325-8. [DOI] [PubMed] [Google Scholar]
  31. Taurog J. D., Sandberg G. P., Mahowald M. L. The cellular basis of adjuvant arthritis. II. Characterization of the cells mediating passive transfer. Cell Immunol. 1983 Aug;80(1):198–204. doi: 10.1016/0008-8749(83)90106-5. [DOI] [PubMed] [Google Scholar]
  32. Tellides G., Dallman M. J., Kupiec-Weglinski J. W., Diamantstein T., Morris P. J. Functional blocking of the interleukin-2 receptor (IL-2R) may be important in the efficacy of IL-2R antibody therapy. Transplant Proc. 1987 Oct;19(5):4231–4233. [PubMed] [Google Scholar]
  33. Tsudo M., Goldman C. K., Bongiovanni K. F., Chan W. C., Winton E. F., Yagita M., Grimm E. A., Waldmann T. A. The p75 peptide is the receptor for interleukin 2 expressed on large granular lymphocytes and is responsible for the interleukin 2 activation of these cells. Proc Natl Acad Sci U S A. 1987 Aug;84(15):5394–5398. doi: 10.1073/pnas.84.15.5394. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. WAKSMAN B. H., WENNERSTEN C. PASSIVE TRANSFER OF ADJUVANT ARTHRITIS IN RATS WITH LIVING LYMPHOID CELLS OF SENSITIZED DONORS. Int Arch Allergy Appl Immunol. 1963;23:129–139. doi: 10.1159/000229412. [DOI] [PubMed] [Google Scholar]
  35. Waldor M. K., Sriram S., Hardy R., Herzenberg L. A., Herzenberg L. A., Lanier L., Lim M., Steinman L. Reversal of experimental allergic encephalomyelitis with monoclonal antibody to a T-cell subset marker. Science. 1985 Jan 25;227(4685):415–417. doi: 10.1126/science.3155574. [DOI] [PubMed] [Google Scholar]
  36. Wofsy D., Seaman W. E. Successful treatment of autoimmunity in NZB/NZW F1 mice with monoclonal antibody to L3T4. J Exp Med. 1985 Feb 1;161(2):378–391. doi: 10.1084/jem.161.2.378. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Yocum D. E., Allen J. B., Wahl S. M., Calandra G. B., Wilder R. L. Inhibition by cyclosporin A of streptococcal cell wall-induced arthritis and hepatic granulomas in rats. Arthritis Rheum. 1986 Feb;29(2):262–273. doi: 10.1002/art.1780290215. [DOI] [PubMed] [Google Scholar]

Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences

RESOURCES